In the second-line setting, pembrolizumab (anti-PD-1 antibody) monotherapy and nivolumab (anti-PD-1 antibody) plus ipilimumab (anti-CTLA4 antibody) have been approved for advanced-stage HCC [111,112] (Table 1). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.